Investor's Business Daily on MSN2h
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, ...
Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...
Though the Healthy Skepticism ads don’t specifically call out compounded GLP-1s, Lilly said in a statement to MM+M that ...
HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
On Monday, the company reported a 3.2% increase in first-half net income to R2.39bn. Aspen Pharmacare’s profit climbed after ...
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback